Neurodegenerative Drugs - Global Strategic Business Report

The global market for Neurodegenerative Drugs is estimated at US$42.8 Billion in 2023 and is projected to reach US$57.3 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Multiple Sclerosis Drugs segment, which is expected to reach US$38.3 Billion by 2030 with a CAGR of a 4.6%. The Parkinson`s Drugs segment is also set to grow at 3.7% CAGR over the next 7 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $11.6 Billion in 2023, and China, forecasted to grow at an impressive 7.3% CAGR to reach $12.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Neurodegenerative Drugs Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neurodegenerative Drugs Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Neurodegenerative Drugs Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Biogen, Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co., Ltd., and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 163 Featured):

Biogen, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Co., Ltd.
Eisai Co., Ltd.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
H. Lundbeck A/S
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Novartis International AG
Pfizer, Inc.
Reata Pharmaceuticals, Inc.
Sage Therapeutics, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
UCB SA

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Neurodegenerative Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for Neurodegenerative Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 3: World 16-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 6: World 16-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 8: World Historic Review for Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 9: World 16-Year Perspective for Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 11: World Historic Review for Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 12: World 16-Year Perspective for Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 13: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 14: World Historic Review for Spinal Muscular Atrophy (SMA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 15: World 16-Year Perspective for Spinal Muscular Atrophy (SMA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 16: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 17: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 18: World 16-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 19: World Neurodegenerative Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 20: USA Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 21: USA Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: USA 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

CANADA

Table 23: Canada Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 24: Canada Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: Canada 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

JAPAN

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 26: Japan Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 27: Japan Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: Japan 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

CHINA

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 29: China Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 30: China Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: China 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

EUROPE

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 32: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 33: Europe Historic Review for Neurodegenerative Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: Europe 16-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 35: Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: Europe 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

FRANCE

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 38: France Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: France Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: France 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

GERMANY

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 41: Germany Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: Germany Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: Germany 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

ITALY

Table 44: Italy Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: Italy Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: Italy 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

UNITED KINGDOM

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 47: UK Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 48: UK Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: UK 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

SPAIN

Table 50: Spain Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Spain Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: Spain 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

RUSSIA

Table 53: Russia Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 54: Russia Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 55: Russia 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 56: Rest of Europe Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 57: Rest of Europe Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 58: Rest of Europe 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 60: Asia-Pacific Historic Review for Neurodegenerative Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 61: Asia-Pacific 16-Year Perspective for Neurodegenerative Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 63: Asia-Pacific Historic Review for Neurodegenerative Drugs by Disease Indication - Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 64: Asia-Pacific 16-Year Perspective for Neurodegenerative Drugs by Disease Indication - Percentage Breakdown of Value Sales for Multiple Sclerosis, Parkinson`s, Alzheimer`s, Spinal Muscular Atrophy (SMA) and Other Disease Indications for the Years 2014, 2024 & 2030

AUSTRALIA

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

Neurodegenerative Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Biogen, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Co., Ltd.
Eisai Co., Ltd.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
H. Lundbeck A/S
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Novartis International AG
Pfizer, Inc.
Reata Pharmaceuticals, Inc.
Sage Therapeutics, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
UCB SA

Table Information

Report Attribute	Details
No. of Pages	344
Published	November 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 42.8 Billion
Forecasted Market Value ( USD ) by 2030	$ 57.3 Billion
Compound Annual Growth Rate	4.2%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5328EUR$5,450USD£4,450GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10123EUR$10,355USD£8,456GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15984EUR$16,350USD£13,351GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 163 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Neurodegenerative Diseases Drugs Market Report and Forecast 2024-2032

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

Neurodegenerative Drugs Market by Drug Class, Indication, Sales Channel - Global Forecast 2025-2030

Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Spinal Muscular Atrophy - Global Strategic Business Report